MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-MP-23-0015817
Market Cap
₹109 Cr
ALPA · NSE
Share Price
₹52.20
+0.56% today
Revenue
₹106 Cr
FY 2025-26 · -5.9% YoY
EBITDA
₹3.29 Cr
Margin 3.1%
Net Profit
₹15.01 Cr
FY 2025-26 · -23.1% YoY
P/E (TTM)
25.0x
P/B 0.6x
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹21.04 Cr
Issued & subscribed
About Alpa Laboratories Limited
Data last updated:
Alpa Laboratories Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 March 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L85195MP1988PLC004446. Its GSTIN is 23AACCA8437C2Z2 (Madhya Pradesh). The company holds 7 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532878 and NSE: ALPA.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹21.04 Cr. It was formerly known as Alpa Laboratories Private Limited. It is led by directors including Mahendra Singh Chawla (Whole-Time Director) and Pravin Chandra Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 33/2 A.B. Road Pigdamber Rao, Indore, Madhya Pradesh, India – 453446.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹105.81 Cr, a decline of 5.9% compared to the previous year. For the same year it recorded a net profit of ₹15.01 Cr (net margin 14.2%) and EBITDA of ₹3.29 Cr (EBITDA margin 3.1%). The net worth stands at ₹186.28 Cr (up 8.2% YoY). Total assets are valued at ₹188.79 Cr (up 9.6% YoY).
The company has about 367 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 2 brands: Alpa Labs and Alpa Labs. As per MCA filings, the company has open charges of ₹26 Cr and satisfied charges of ₹81.73 Cr on record. Court records list 39 cases involving the company, including 15 filed by the company and 24 filed against it; 4 cases are pending. The company has 44 deals on record (42 market trades, 1 acquisition, 1 ipo); the latest was in September 2024. Its 10 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Palsons Derma Private Limited with revenue of ₹137.11 Cr. The company has 5 MSME Form 1 returns on record between 2019 and 2020, listing 129 overdue payments to 3 micro and small suppliers.
Alpa Laboratories Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-MP-23-0015817). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alpalabs.in.
Company details
CIN L85195MP1988PLC004446
Registration Number 004446
Incorporation Date 18 March 1988
ROC Gwalior
Listing Status Listed - Listed on NSE (ALPA); Listed on BSE (532878)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-MP-23-0015817
CIN history
Alpa Laboratories has one previous CIN (Corporate Identification Number): U85195MP1988PLC004446. The current CIN is L85195MP1988PLC004446, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195MP1988PLC004446 | Current |
| U85195MP1988PLC004446 | Previous |
Key People
Mahendra Singh Chawla Whole-Time Director Pravin Chandra Shah Whole-Time Director Shitul Shah Whole-Time Director Recognitions & Rankings of Alpa Laboratories
Contact details
Alpa Laboratories Limited's registered office is in Indore, Madhya Pradesh. Its website is alpalabs.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address33/2 A.B. Road Pigdamber Rao, Indore, Madhya Pradesh, India – 453446
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Alpa Laboratories Limited, buy the company report.
Comprehensive company report
Alpa Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Alpa Laboratories operates two associated brands: Alpa Labs and Alpa Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic drugs manufacturer & exporter | alpalabs.com | |
| Alpa Labs is engaged in manufacturing pharmaceutical dosage forms. | alpalabs.in |
Business activity
The main business activity of Alpa Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Alpa Laboratories Limited, buy the company report.
Financials of Alpa Laboratories Limited
FY 2025-26 filings availableAlpa Laboratories Limited reported revenue of ₹105.81 Cr (down 5.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹106 Cr
-5.9% YoY
EBITDA
₹3.29 Cr
-30.6% YoY
Profit After Tax
₹15.01 Cr
-23.1% YoY
Net Worth
₹186 Cr
+8.2% YoY
Total Assets
₹189 Cr
+9.6% YoY
Total Debt
₹2.51 Cr
+8266.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 106 | 112 | 109 | 92.96 | 112 | 97.55 | 85.97 |
| Revenue growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| EBITDA | 3.29 | 4.74 | 8.10 | 8.08 | 10.67 | 7.68 | 3.34 |
| EBITDA margin | +3.1% | +4.2% | +7.5% | +8.7% | +9.5% | +7.9% | +3.9% |
| Profit before tax | 16.70 | 25.66 | 20.68 | 15.90 | 19.57 | 10.77 | 2.89 |
| Net profit | 15.01 | 19.53 | 17.21 | 12.60 | 7.73 | 5.17 | 2.62 |
| Net profit margin | +14.2% | +17.4% | +15.8% | +13.6% | +6.9% | +5.3% | +3.1% |
| EPS (₹) | 6.71 | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 | 0.88 |
| Balance sheet | |||||||
| Total assets | 189 | 172 | 157 | 137 | 128 | 108 | 101 |
| Net worth | 186 | 172 | 152 | 135 | 122 | 108 | 100 |
| Total debt | 2.51 | 0.03 | 5.25 | 2.30 | 5.85 | 0.19 | 0.41 |
| Cash & bank | 2.85 | 2.22 | 1.71 | 8.81 | 1.58 | 10.51 | 6.17 |
| Net working capital | 25.84 | 35.32 | 47.02 | 48.99 | 41.66 | 48.07 | 35.61 |
| Cash flow | |||||||
| Cash from operations | 9.29 | 18.32 | 3.65 | 8.90 | 9.94 | (1.71) | 17.78 |
| Cash from investing | (10.88) | (12.36) | (13.34) | 2.13 | (15.61) | 5.86 | (11.16) |
| Cash from financing | 2.22 | (5.44) | 2.58 | (3.79) | 5.44 | 0.19 | (1.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.93 | 31.40 | 29.05 | 26.26 | 19.11 | 39.92 | 26.15 | 24.94 |
| Revenue growth (YoY) | +25.2% | -21.3% | +11.1% | +5.3% | -10.9% | - | - | - |
| Other income | 5.77 | (0.16) | 0.91 | 3.06 | 11.94 | 2.48 | 8.80 | 6.91 |
| EBITDA | (3.96) | 3.60 | 1.51 | (2.24) | 0.42 | 0.20 | 0.74 | 3.32 |
| EBITDA margin | -16.5% | +11.5% | +5.2% | -8.5% | +2.2% | +0.5% | +2.8% | +13.3% |
| Depreciation | 0.72 | 0.22 | 0.65 | 0.67 | 0.55 | 0.58 | 0.55 | 0.53 |
| Interest | 0.11 | 0.15 | 0.03 | 0.03 | 0.05 | 0.02 | 0.09 | 0.05 |
| Profit before tax | 0.98 | 3.07 | 1.74 | 0.12 | 11.76 | 2.08 | 8.90 | 9.65 |
| Tax | 0.00 | 1.69 | 0.16 | 0.00 | 0.00 | 4.20 | 0.00 | 1.96 |
| Net profit | 0.98 | 1.38 | 1.58 | 0.12 | 11.76 | (2.12) | 8.90 | 7.69 |
| EPS (₹) | 0.49 | 0.24 | 0.76 | 0.05 | 5.59 | (0.95) | 4.23 | 3.66 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 106 | 112 | 109 | 92.96 | 112 | 97.55 | 85.97 |
| Revenue growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| EBITDA | 3.30 | 5.00 | 8.14 | 8.08 | 10.70 | 7.69 | 3.44 |
| EBITDA margin | +3.1% | +4.5% | +7.5% | +8.7% | +9.5% | +7.9% | +4.0% |
| Profit before tax | 16.64 | 25.84 | 20.67 | 15.94 | 19.59 | 10.77 | 5.07 |
| Net profit | 14.95 | 19.72 | 17.20 | 12.64 | 7.76 | 5.14 | 5.38 |
| Net profit margin | +14.1% | +17.5% | +15.8% | +13.6% | +6.9% | +5.3% | +6.3% |
| EPS (₹) | 6.69 | 9.35 | 7.97 | 6.00 | 6.71 | 3.45 | 1.94 |
| Balance sheet | |||||||
| Total assets | 198 | 182 | 167 | 148 | 137 | 118 | 111 |
| Net worth | 197 | 182 | 162 | 145 | 132 | 118 | 110 |
| Total debt | 1.51 | 0.03 | 5.25 | 2.59 | 5.85 | 0.19 | 0.41 |
| Cash & bank | 1.21 | 1.68 | 1.26 | 8.74 | 1.31 | 10.24 | 5.92 |
| Net working capital | 23.77 | 34.30 | 45.84 | 48.67 | 43.03 | 46.89 | 34.44 |
| Cash flow | |||||||
| Cash from operations | 9.95 | 18.39 | 3.70 | 10.20 | 2.20 | (1.47) | 17.66 |
| Cash from investing | (11.58) | (12.49) | (13.45) | 1.17 | (15.61) | 5.82 | (11.27) |
| Cash from financing | 1.16 | (5.48) | 2.26 | (3.48) | 5.41 | (0.03) | (1.35) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.93 | 31.40 | 29.67 | 25.63 | 19.11 | 39.11 | 26.15 | 24.94 |
| Revenue growth (YoY) | +25.2% | -19.7% | +13.5% | +2.8% | -10.9% | - | - | - |
| Other income | 5.83 | (0.18) | 0.26 | 3.69 | 11.96 | 3.24 | 8.80 | 6.91 |
| Total expenses | 27.89 | 27.78 | 27.53 | 28.50 | 18.69 | 39.47 | 25.41 | 21.67 |
| EBITDA | (3.96) | 3.62 | 2.14 | (2.87) | 0.42 | (0.36) | 0.74 | 3.27 |
| EBITDA margin | -16.5% | +11.5% | +7.2% | -11.2% | +2.2% | -0.9% | +2.8% | +13.1% |
| Depreciation | 0.72 | 0.22 | 0.65 | 0.67 | 0.55 | 0.58 | 0.55 | 0.53 |
| Interest | 0.11 | 0.16 | 0.03 | 0.05 | 0.05 | 0.05 | 0.10 | 0.06 |
| Profit before tax | 1.04 | 3.06 | 1.72 | 0.10 | 11.78 | 2.25 | 8.89 | 9.59 |
| Tax | 0.00 | 1.69 | (0.16) | 0.00 | 0.00 | 4.20 | 0.00 | 1.96 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.93 | 31.40 | 29.05 | 26.26 | 19.11 | 39.92 | 26.15 | 24.94 |
| Revenue growth (YoY) | +25.2% | -21.3% | +11.1% | +5.3% | -10.9% | - | - | - |
| Other income | 5.77 | (0.16) | 0.91 | 3.06 | 11.94 | 2.48 | 8.80 | 6.91 |
| EBITDA | (3.96) | 3.60 | 1.51 | (2.24) | 0.42 | 0.20 | 0.74 | 3.32 |
| EBITDA margin | -16.5% | +11.5% | +5.2% | -8.5% | +2.2% | +0.5% | +2.8% | +13.3% |
| Depreciation | 0.72 | 0.22 | 0.65 | 0.67 | 0.55 | 0.58 | 0.55 | 0.53 |
| Interest | 0.11 | 0.15 | 0.03 | 0.03 | 0.05 | 0.02 | 0.09 | 0.05 |
| Profit before tax | 0.98 | 3.07 | 1.74 | 0.12 | 11.76 | 2.08 | 8.90 | 9.65 |
| Tax | 0.00 | 1.69 | 0.16 | 0.00 | 0.00 | 4.20 | 0.00 | 1.96 |
| Net profit | 0.98 | 1.38 | 1.58 | 0.12 | 11.76 | (2.12) | 8.90 | 7.69 |
| EPS (₹) | 0.49 | 0.24 | 0.76 | 0.05 | 5.59 | (0.95) | 4.23 | 3.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 112 | 109 | 92.96 | 112 | 97.55 | 85.97 |
| Revenue growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| Other income | 15.76 | 23.35 | 14.89 | 9.37 | 10.78 | 4.40 | 2.91 |
| Total expenses | 103 | 108 | 101 | 84.88 | 102 | 89.87 | 82.63 |
| Employee cost | 0.00 | 14.39 | 13.29 | 12.17 | 11.93 | 11.75 | 11.82 |
| EBITDA | 3.29 | 4.74 | 8.10 | 8.08 | 10.67 | 7.68 | 3.34 |
| EBITDA margin | +3.1% | +4.2% | +7.5% | +8.7% | +9.5% | +7.9% | +3.9% |
| Depreciation | 2.09 | 2.20 | 1.95 | 1.33 | 1.66 | 1.23 | 3.16 |
| Interest | 0.26 | 0.23 | 0.36 | 0.22 | 0.22 | 0.08 | 0.20 |
| Profit before tax | 16.70 | 25.66 | 20.68 | 15.90 | 19.57 | 10.77 | 2.89 |
| Tax | 1.69 | 6.17 | 3.90 | 3.31 | 5.47 | 3.54 | 1.06 |
| Net profit | 15.01 | 19.53 | 17.21 | 12.60 | 7.73 | 5.17 | 2.62 |
| Net profit margin | +14.2% | +17.4% | +15.8% | +13.6% | +6.9% | +5.3% | +3.1% |
| EPS (₹) | 6.71 | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 | 0.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 |
| Reserves & surplus | 165 | 151 | 131 | 114 | 101 | 86.60 | 79.33 |
| Shareholders' funds (net worth) | 186 | 172 | 152 | 135 | 122 | 108 | 100 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 2.51 | 0.03 | 4.46 | 2.30 | 4.47 | 0.01 | 0.41 |
| Unsecured loans | 0.00 | 0.00 | 0.79 | 0.00 | 1.38 | 0.18 | 0.00 |
| Total debt | 2.51 | 0.03 | 5.25 | 2.30 | 5.85 | 0.19 | 0.41 |
| Total liabilities | 189 | 172 | 157 | 137 | 128 | 108 | 101 |
| Assets | |||||||
| Gross block | 52.11 | 51.22 | 39.84 | 33.46 | 34.41 | 30.64 | 30.01 |
| Net block | 20.16 | 21.36 | 11.47 | 7.04 | 9.32 | 7.21 | 6.40 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.58 | 0.81 |
| Investments | 142 | 118 | 98.01 | 78.45 | 74.63 | 50.84 | 56.58 |
| Inventories | 13.33 | 17.64 | 13.67 | 12.64 | 15.46 | 16.56 | 12.55 |
| Sundry debtors | 40.83 | 46.83 | 41.15 | 46.73 | 38.04 | 35.43 | 24.59 |
| Cash & bank balances | 2.85 | 2.22 | 1.71 | 8.81 | 1.58 | 10.51 | 6.17 |
| Loans & advances | 18.85 | 15.30 | 13.31 | 8.91 | 14.24 | 17.89 | 12.86 |
| Total current assets | 75.86 | 81.99 | 69.84 | 77.09 | 69.32 | 80.39 | 56.17 |
| Total current liabilities | 50.02 | 46.67 | 22.82 | 28.10 | 27.66 | 32.32 | 20.56 |
| Net working capital | 25.84 | 35.32 | 47.02 | 48.99 | 41.66 | 48.07 | 35.61 |
| Total assets | 189 | 172 | 157 | 137 | 128 | 108 | 101 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.62 | 3.11 | 10.21 | 1.58 | 1.80 | 6.17 | 0.90 |
| Net cash from operating activities | 9.29 | 18.32 | 3.65 | 8.90 | 9.94 | (1.71) | 17.78 |
| Net cash from investing activities | (10.88) | (12.36) | (13.34) | 2.13 | (15.61) | 5.86 | (11.16) |
| Net cash from financing activities | 2.22 | (5.44) | 2.58 | (3.79) | 5.44 | 0.19 | (1.35) |
| Net change in cash | 0.63 | 0.51 | (7.10) | 7.24 | (0.23) | 4.34 | 5.27 |
| Closing cash | 2.85 | 2.22 | 1.71 | 8.81 | 1.58 | 10.51 | 6.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| EBITDA growth | -30.6% | -41.5% | +0.3% | -24.3% | +38.9% | +129.9% | - |
| PBT growth | -34.9% | +24.1% | +30.1% | -18.8% | +81.7% | +272.7% | +4.7% |
| Net income growth | -23.1% | +13.5% | +36.6% | +63.0% | +49.5% | +97.3% | - |
| Revenue CAGR (3Y) | +4.4% | +0.1% | +3.7% | +2.6% | +12.9% | +15.8% | +10.7% |
| EBITDA CAGR (3Y) | -25.9% | -23.7% | +1.8% | +34.2% | +110.1% | +25.0% | -12.6% |
| Profitability & leverage | |||||||
| Net income margin | +14.2% | +17.3% | +15.4% | +13.5% | +12.6% | +7.4% | +2.1% |
| Return on capital employed | - | +15.8% | +14.3% | +12.2% | +9.3% | +7.4% | +5.4% |
| Return on net worth | - | +12.1% | +11.7% | +9.8% | +6.7% | +5.0% | +2.7% |
| Debt / equity | - | 0.02 | 0.03 | 0.03 | 0.03 | 0.00 | 0.01 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest cover | 21.67 | 9.06 | 5.85 | 3.26 | 2.44 | 1.24 | 111.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.47 | 2.97 | 2.74 | 3.45 | 3.22 | 2.50 |
| Inventory turnover | - | 7.18 | 8.27 | 6.62 | 7.01 | 6.70 | 6.47 |
| Debtors turnover | - | 2.56 | 2.47 | 2.19 | 3.06 | 3.25 | 3.15 |
| EPS (₹) | 6.71 | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 | 0.88 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 81.48 | 72.20 | 63.96 | 57.86 | 51.16 | 47.70 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.93 | 31.40 | 29.67 | 25.63 | 19.11 | 39.11 | 26.15 | 24.94 |
| Revenue growth (YoY) | +25.2% | -19.7% | +13.5% | +2.8% | -10.9% | - | - | - |
| Other income | 5.83 | (0.18) | 0.26 | 3.69 | 11.96 | 3.24 | 8.80 | 6.91 |
| Total expenses | 27.89 | 27.78 | 27.53 | 28.50 | 18.69 | 39.47 | 25.41 | 21.67 |
| EBITDA | (3.96) | 3.62 | 2.14 | (2.87) | 0.42 | (0.36) | 0.74 | 3.27 |
| EBITDA margin | -16.5% | +11.5% | +7.2% | -11.2% | +2.2% | -0.9% | +2.8% | +13.1% |
| Depreciation | 0.72 | 0.22 | 0.65 | 0.67 | 0.55 | 0.58 | 0.55 | 0.53 |
| Interest | 0.11 | 0.16 | 0.03 | 0.05 | 0.05 | 0.05 | 0.10 | 0.06 |
| Profit before tax | 1.04 | 3.06 | 1.72 | 0.10 | 11.78 | 2.25 | 8.89 | 9.59 |
| Tax | 0.00 | 1.69 | (0.16) | 0.00 | 0.00 | 4.20 | 0.00 | 1.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 112 | 109 | 92.96 | 112 | 97.55 | 85.97 |
| Revenue growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| Other income | 15.72 | 23.31 | 14.87 | 9.41 | 10.79 | 4.41 | 2.97 |
| Total expenses | 103 | 107 | 101 | 84.88 | 102 | 89.86 | 82.53 |
| Employee cost | 0.00 | 14.37 | 13.26 | 12.17 | 11.93 | 11.75 | 11.82 |
| EBITDA | 3.30 | 5.00 | 8.14 | 8.08 | 10.70 | 7.69 | 3.44 |
| EBITDA margin | +3.1% | +4.5% | +7.5% | +8.7% | +9.5% | +7.9% | +4.0% |
| Depreciation | 2.09 | 2.20 | 1.95 | 1.33 | 1.66 | 1.23 | 1.14 |
| Interest | 0.29 | 0.27 | 0.39 | 0.22 | 0.24 | 0.10 | 0.20 |
| Profit before tax | 16.64 | 25.84 | 20.67 | 15.94 | 19.59 | 10.77 | 5.07 |
| Tax | 1.69 | 6.16 | 3.90 | 3.31 | 5.45 | 3.53 | 1.00 |
| Net profit | 14.95 | 19.72 | 17.20 | 12.64 | 7.76 | 5.14 | 5.38 |
| Net profit margin | +14.1% | +17.5% | +15.8% | +13.6% | +6.9% | +5.3% | +6.3% |
| EPS (₹) | 6.69 | 9.35 | 7.97 | 6.00 | 6.71 | 3.45 | 1.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 | 21.04 |
| Reserves & surplus | 176 | 161 | 141 | 124 | 111 | 96.48 | 89.19 |
| Shareholders' funds (net worth) | 197 | 182 | 162 | 145 | 132 | 118 | 110 |
| Secured loans | 1.51 | 0.03 | 4.46 | 2.30 | 4.47 | 0.01 | 0.41 |
| Unsecured loans | 0.00 | 0.00 | 0.79 | 0.29 | 1.38 | 0.18 | 0.00 |
| Total debt | 1.51 | 0.03 | 5.25 | 2.59 | 5.85 | 0.19 | 0.41 |
| Total liabilities | 198 | 182 | 167 | 148 | 137 | 118 | 111 |
| Assets | |||||||
| Gross block | 52.11 | 51.22 | 39.84 | 33.46 | 34.41 | 30.64 | 30.01 |
| Net block | 20.16 | 20.65 | 11.47 | 7.04 | 9.32 | 7.21 | 6.40 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 0.81 |
| Investments | 153 | 129 | 109 | 89.60 | 85.73 | 61.93 | 67.61 |
| Inventories | 13.33 | 17.64 | 13.67 | 12.64 | 15.46 | 16.56 | 12.55 |
| Sundry debtors | 40.83 | 46.83 | 41.15 | 47.37 | 38.04 | 35.43 | 24.59 |
| Cash & bank balances | 1.21 | 1.68 | 1.26 | 8.74 | 1.31 | 10.24 | 5.92 |
| Loans & advances | 18.35 | 14.81 | 12.56 | 8.02 | 13.30 | 16.96 | 11.94 |
| Total current assets | 73.72 | 80.96 | 68.64 | 76.77 | 68.11 | 79.19 | 55.00 |
| Total current liabilities | 49.95 | 46.66 | 22.80 | 28.10 | 25.08 | 32.30 | 20.56 |
| Net working capital | 23.77 | 34.30 | 45.84 | 48.67 | 43.03 | 46.89 | 34.44 |
| Total assets | 198 | 182 | 167 | 148 | 137 | 118 | 111 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.08 | 2.62 | 10.14 | 2.24 | 10.85 | 5.92 | 0.88 |
| Net cash from operating activities | 9.95 | 18.39 | 3.70 | 10.20 | 2.20 | (1.47) | 17.66 |
| Net cash from investing activities | (11.58) | (12.49) | (13.45) | 1.17 | (15.61) | 5.82 | (11.27) |
| Net cash from financing activities | 1.16 | (5.48) | 2.26 | (3.48) | 5.41 | (0.03) | (1.35) |
| Net change in cash | (0.47) | 0.43 | (7.49) | 7.89 | (7.99) | 4.32 | 5.03 |
| Closing cash | 1.21 | 1.68 | 1.26 | 8.74 | 1.31 | 10.24 | 5.92 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -5.9% | +3.4% | +17.0% | -17.2% | +15.1% | +13.5% | - |
| EBITDA growth | -34.0% | -38.6% | +0.7% | -24.5% | +39.1% | +123.6% | - |
| PBT growth | -35.6% | +25.0% | +29.7% | -18.6% | +81.9% | +112.4% | +9.7% |
| Net income growth | -24.2% | +14.7% | +36.1% | +62.9% | +51.0% | -4.5% | - |
| Revenue CAGR (3Y) | +4.4% | +0.1% | +3.7% | +2.6% | +12.9% | +16.1% | +10.7% |
| EBITDA CAGR (3Y) | -25.8% | -22.4% | +1.9% | +32.9% | +106.2% | +24.8% | -11.7% |
| Profitability & leverage | |||||||
| Net income margin | +14.1% | +17.5% | +15.4% | +13.6% | +12.6% | +7.4% | +4.7% |
| Return on capital employed | - | +15.0% | +13.4% | +11.3% | +8.6% | +6.8% | +6.8% |
| Return on net worth | - | +11.5% | +10.9% | +9.1% | +6.2% | +4.5% | +5.0% |
| Debt / equity | - | 0.02 | 0.03 | 0.03 | 0.02 | 0.00 | 0.01 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest cover | 23.97 | 9.64 | 6.30 | 3.26 | 2.65 | 1.55 | 8.70 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.47 | 2.97 | 2.74 | 3.45 | 3.22 | 2.93 |
| Inventory turnover | - | 7.18 | 8.27 | 6.62 | 7.01 | 6.70 | 6.47 |
| Debtors turnover | - | 2.56 | 2.46 | 2.18 | 3.06 | 3.25 | 3.16 |
| EPS (₹) | 6.69 | 9.35 | 7.97 | 6.00 | 6.71 | 3.45 | 1.94 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 86.41 | 76.98 | 68.97 | 62.56 | 55.85 | 52.39 |
To see the full year-wise statements and ratios of Alpa Laboratories Limited, buy the company report.
Board of directors of Alpa Laboratories Limited
Alpa Laboratories has 9 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahendra Singh Chawla Also directs: Norfolk Mercantile Private Limited | Whole-Time Director | 18 Mar 1988 | 38 Years 7 Months | Current |
| Pravin Chandra Shah Also directs: Norfolk Mercantile Private Limited | Whole-Time Director | 01 Mar 2009 | 17 Years 7 Months | Current |
| Paresh Chawla | Director | 28 May 2016 | 10 Years 5 Months | Current |
| Vitthal Kothana | Director | 13 Aug 2022 | 4 Years 2 Months | Current |
| Pratik Shah | Director | 31 Aug 2024 | 2 Years 1 Months | Current |
| Shitul Shah Also directs: Wealthpile Trading LLP | Whole-Time Director | 14 Aug 2023 | 3 Years 2 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Alpa Laboratories Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Palsons Derma Private Limited | ₹137.11 Cr (FY 2025) | 15.0% | Kolkata, West Bengal, India | |||
| Maxwell Life Science Limited | ₹136.55 Cr (FY 2025) | 67.0% | Mumbai, Maharashtra, India | |||
| Lewens Labs Private Limited | ₹136.52 Cr (FY 2025) | 12.0% | Bharuch, Gujarat, India | |||
| Naari Pharma Private Limited | ₹136.35 Cr (FY 2025) | 14.0% | Bangalore, Karnataka, India | |||
| Zenith Drugs Limited | ₹135.93 Cr (FY 2025) | 2.0% | Indore, Madhya Pradesh, India | |||
| Ravoo's Laboratories Limited | ₹134.97 Cr (FY 2024) | 4.0% | Hyderabad, Telangana, India | |||
| Surabhi Industries (India) Private Limited | ₹133.75 Cr (FY 2024) | -37.0% | Hyderabad, Telangana, India | |||
| Vikram Thermo (India) Limited | ₹133.72 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Strassenburg Pharmaceuticals Private Ltd. | ₹133.69 Cr (FY 2025) | 13.0% | Kolkata, West Bengal, India | |||
| Hemmo Pharmaceuticals Private Limited | ₹133.32 Cr (FY 2021) | 45.0% | Mumbai, Maharashtra, India | |||
| Alpa Laboratories Limitedthis company | ₹105.81 Cr (FY 2026) | ₹15.01 Cr | 14.2% | -5.9% | 367 | Indore, Madhya Pradesh, India |
To see the full peer comparison of Alpa Laboratories Limited, buy the company report.
Auditor
Alpa Laboratories Limited is audited by C.H. Padliya & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| C.H. Padliya & Co. | FY 2024 | 003151C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 57.20%, foreign institutional investors hold 0.40%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 42.40%.
Sep 2026
QUARTER
57.20% Promoters
0.40% FII (Foreign Institutional)
42.40% Retail & Others
Promoter holding - history
Now 57.20% · Sep 2026High 57.30% · Dec 2025Low 57.20% · Jun 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 57.20% | 57.20% | 57.30% | 57.30% |
| Public | 42.80% | 42.80% | 42.70% | 42.70% |
Charges & borrowings
Open charges
₹26 Cr
Satisfied charges
₹81.73 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Jul 2025 | 101142713 | Hdfc Bank Limited | ₹7 Cr | Open | |
| 06 Jan 2024 | 100845955 | Hdfc Bank Limited | ₹5 Cr | Open | |
| 06 Dec 2017 | 100139390 | Others | ₹14 Cr | Open | |
| 24 Apr 2019 | 100262538 | Yes Bank Limited | ₹10 Cr | Satisfied | |
| 01 Sep 2017 | 100134584 | Hdfc Bank Limited | ₹37 Lakh | Satisfied |
To see the full charge records of Alpa Laboratories Limited, buy the company report.
Total charge records: 13 View all charges
Deals & funding
Alpa Laboratories Limited has 44 deals on record (42 market trades, 1 acquisition, 1 ipo); the latest was in September 2024.
Total deals
44
Market trades
42
Acquisition
1
IPO
1
Deals on record (5 of 44)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2024 | Market trade | ₹16.56 Cr | Buyer: Aakraya Research LLP , Qe Securities LLP , NK Securities Research Private Limited Seller: Aakraya Research LLP , Qe Securities LLP , NK Securities Research Private Limited |
| Sep 2024 | Market trade | ₹2.4 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
| Sep 2024 | Market trade | ₹1.34 Cr | Buyer: Hrti Private Limited Seller: Hrti Private Limited |
| Sep 2024 | Market trade | ₹3.77 Cr | Buyer: NK Securities Research Private Limited , Hrti Private Limited , Qe Securities LLP Seller: NK Securities Research Private Limited , Qe Securities LLP , Hrti Private Limited |
| Feb 2024 | Market trade | ₹1.31 Cr | Buyer: Citadel Securities India Markets Private Limited Seller: Citadel Securities India Markets Private Limited |
To see the full deal history of Alpa Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Alpa Laboratories Limited has 39 court cases on record: 15 filed by Alpa Laboratories, 24 filed against it. 4 cases are pending and 35 are disposed.
Total cases
39
Filed by the company
15
Filed against the company
24
Pending
4
Disposed
35
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 21 | 17 | 4 |
| High courts | 12 | 5 | 0 |
| Supreme Court | 6 | 2 | 0 |
Cases on record (5 of 39)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (1801-Ordinary Civil Matters : T.P. Under Article 139A(1) of the Constitution of India) | Filed against the company by Troikaa Pharmaceuticals Ltd Commence House I, Opposite Rajvansh Apartments, Judges Bungalow Road ,Ahmedabad , Gujarat | Disposed |
| High Court of Delhi | Court case (O.M.P.) | Filed against the company by M/S Ranbaxy Laboratories Ltd | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by Anand Healthcare Limited | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by Cadila Pharmaceuticals Ltd. | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by Procter and Gamble Hygiene and Health Care Ltd and Ors | Disposed |
To see the full case history of Alpa Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Alpa Laboratories Limited was last rated by Crisil on 28 Dec 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 28 Dec 2020 |
To see the full credit ratings and regulatory alerts of Alpa Laboratories Limited, buy the company report.
MSME payment delays
Alpa Laboratories Limited has 5 MSME Form 1 returns on record between 2019 and 2020, listing 129 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (3 of 3)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Doer Packaging Private Limited | |||
| Indiana Chem-Port | |||
| Bhasin Packwell Pvt Ltd |
To see the full MSME payment records of Alpa Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Alpa Laboratories has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Norfolk Mercantile Private Limited | U74120MH2014PTC252923 |
To see the full group structure of Alpa Laboratories Limited, buy the company report.
Employees & EPFO
Alpa Laboratories Limited has a workforce of 367 employees on its EPFO records as of Apr 09, 2024, across 2 active EPFO establishments.
Employee count
367
Active EPFO establishments
2
Employee growth
2.8%
GST
Alpa Laboratories has 7 GST registrations: 4 active and 3 cancelled or inactive.
Total GSTINs
7
Active
4
Cancelled / inactive
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AACCA8437C2Z2 | Madhya Pradesh | Active | 01 Jul 2017 |
| 09AACCA8437C2ZS | Uttar Pradesh | Active | 17 Sep 2020 |
| 36AACCA8437C1ZW | Telangana | Active | 22 Sep 2020 |
| 10AACCA8437C2Z9 | Bihar | Active | 11 Nov 2020 |
To see the full GST registrations and return filing status of Alpa Laboratories Limited, buy the company report.
Recent activity
Alpa Laboratories Limited has 30 board changes on record since 1988: 20 appointments and 10 cessations. The latest: Pratik Shah was appointed as Director on 31 Aug 2024.
Filing
Alpa Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Gwalior.
AGM
Alpa Laboratories Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 7.00 Cr with Charge ID 101142713 was registered on 23 Jul 2025.
Charges
A charge with Others of Rs. 14.00 Cr registered on 06 Dec 2017 with Charge ID 100139390 was modified on 03 Apr 2025.
Appointed
Pratik Shah was appointed as Director.
Ceased
Devendra Kumar Baheti ceased to be Director.
Ceased
Krishna Das Malani ceased to be Director.
Ceased
Sharadchandra Lunawat ceased to be Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 5.00 Cr with Charge ID 100845955 was registered on 06 Jan 2024.
Appointed
Pratibha Lunawat was appointed as Director.
Appointed
Sanket Baheti was appointed as Director.
Appointed
Sunil Kumar Valecha was appointed as Director.
50 earlier events are in the company report.
News
Frequently asked questions
Alpa Laboratories is an active public limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 March 1988 (38+ years old) and is registered under CIN L85195MP1988PLC004446. Listed on BSE: 532878 and NSE: ALPA.
Alpa Laboratories reported revenue of ₹105.81 Cr for FY 2025-26 (down 5.9% YoY) based on consolidated financials.
Alpa Laboratories has 9 current directors:
- Mahendra Singh Chawla - Whole-Time Director
- Pravin Chandra Shah - Whole-Time Director
- Shitul Shah - Whole-Time Director
- Paresh Chawla - Director
- Vitthal Kothana - Director
- Pratik Shah - Director
- Sanket Baheti - Director
- Sunil Kumar Valecha - Director
- Pratibha Lunawat - Director
The latest financial statements of Alpa Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Alpa Laboratories is 23AACCA8437C2Z2, registered in Madhya Pradesh. The company has 7 GST registrations in all, of which 4 are active and 3 are cancelled or inactive. Other active GSTINs include 09AACCA8437C2ZS (Uttar Pradesh), 36AACCA8437C1ZW (Telangana), 10AACCA8437C2Z9 (Bihar).
The CIN (Corporate Identification Number) of Alpa Laboratories is L85195MP1988PLC004446. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Alpa Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 532878) and NSE (symbol: ALPA).
Alpa Laboratories has 39 court cases on record: 15 filed by the company and 24 filed against it. 4 are pending. Most are in the district courts.
Alpa Laboratories was incorporated on 18 March 1988, making it 38+ years old. It is registered with the Registrar of Companies, Gwalior.
Alpa Laboratories has 44 deals on record (42 market trades, 1 acquisition, 1 ipo); the latest was in September 2024.
The peers of Alpa Laboratories by revenue are Palsons Derma Private Limited, Maxwell Life Science Limited, Lewens Labs Private Limited, Naari Pharma Private Limited, Zenith Drugs Limited and 5 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pratik Shah was appointed as Director on 31 Aug 2024. Devendra Kumar Baheti ceased to be Director on 31 Mar 2024. Krishna Das Malani ceased to be Director on 31 Mar 2024. Alpa Laboratories has 30 board changes on record in total.